Abbott Laboratories Updates Investors on Health Technology Progress

Abbott Laboratories, a company focused on health technology, has published a series of investor newsletters offering insights into its innovations and financial performance. The newsletters, spanning from 2023 to 2025, cover topics such as new device developments, corporate sustainability reporting, and key results for shareholders.

The most recent updates from September 2025 include a report on the second quarter for its continuous glucose monitoring (CGM) systems, investments in a U.S. manufacturing facility to support health technology advancements, and the 2024 Global Sustainability Report. The fall newsletter also notes Abbott's inclusion on the TIME 100 Most Influential Companies list for 2025.

An earlier newsletter from February 2025 highlighted fourth-quarter results and strong growth momentum heading into 2025. It also featured the opening of a new facility to meet demand for diabetes technology and innovations in structural heart disease treatment.

Publications from July 2024 emphasized Abbott's commitment to sustainability and the U.S. market launch of new consumer biowearable devices, Lingo and Libre Rio. It also detailed the TriClip device offering a new treatment option for individuals with tricuspid regurgitation.

Newsletters from early 2024 reported strong fourth-quarter earnings, a dividend increase for the 52nd consecutive year, and a new chapter in Freestyle Libre technology. Abbott aims to provide accessible and affordable healthcare solutions globally.